Fact CheckerSign in

NCT06558864Not yet recruiting

High Selective Subiculum SEEG Guided RF-TC for mTLE-HS

The Efficacy and Safety of Subiculum Stereotactic-EEG Guided Radio-frequency Thermocoagulation for Mesial Temporal Lobe Epilepsy With Hippocampus Sclerosis: A Prospective, Single-Arm Trial

Source: ClinicalTrials.gov · Last updated 19 Aug 2024 · Not updated for over 12 months - ask the site whether it is still open

Brief summary (registry, in English)

The primary objective of this research is to study the efficacy and safety of Stereotactic EEG (SEEG) guided radio-frequency thermocoagulation (RF-TC) of Subiculum as adjunctive therapy for reducing the frequency of seizures in drug-resistant temporal lobe epilepsy with Mesial temporal lobe epilepsy with hippocampal sclerosis (mTLE-HS).

Status (registry)
Not yet recruiting
Study type
Interventional
Enrollment
20 (estimated)
First submitted
4 Aug 2024
Start date
9 Aug 2024
Primary completion date
20 Aug 2025
Lead sponsor
Xuanwu Hospital, Beijing
Diseases
Epilepsy
NCT number
NCT06558864

What you commit to

  • Study type: Interventional
  • Planned participants: 20
  • From 9 Aug 2024 to the primary completion date, 20 Aug 2025
  • No sites listed in no country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Prior treatment

  • Presence of implanted electrical stimulation medical device anywhere in the body (e.g., pacemaker, spinal cord stimulator, responsive neurostimulation) or any metallic implants in the head (e.g., aneurysm clips, cochlear implants). Note: Vagal nerve stimulators are allowed if the parameter remains stable for at least 3 months prior to the screening visit;

Other illness

  • Diagnosed with generalized or hereditary epilepsy with ion channel gene mutations;
  • Psychogenic non-epileptic seizures within 12 months;
  • Risk factors that would put the participant at risk for intraoperative or postoperative bleeding. (e.g., coagulation abnormalities, etc.) or the need for chronic anticoagulation or antiplatelet aggregation medications;
  • Diagnosed with a progressive neurological disorder (including progressive Rasmussen's encephalitis, etc.);
  • Diagnosed with a severe neuropsychiatric disorder such as dementia, major depression (admission to a psychiatric specialty/hospital within 5 years or any suicidal or self-injurious tendencies), schizophrenia, or neurodegenerative disorders;
  • Diagnosed with other serious physical disorders, internal diseases or severe abnormalities in liver or kidney function;

Other

  • IQ \< 55 or severe cognitive dysfunction, unable to complete the study;
  • Pregnant, or planning to pregnant within 2 years;
  • Participation in another clinical study within 3 months;
  • Not suitable for enrollment as assessed by the multidisciplinary team of the center.

Who the study is looking for

  • Participants are between the ages of 14 -65 years of age
  • Refractory to anti-seizure medications (ASMs).
  • Persistence of disabling seizures at least 2 times per month during the Baseline Phase,with no more than 30 days between seizures during the Baseline Phase.
  • Hippocampal atrophy on MRI T1 imaging with increased ipsilateral mesial signal on T2 imaging
  • Interictal EEG shows focal or lateralized spikes on temporal, frontal zone, or sphenoid electrode
  • Ictal EEG onset is focal or lateralized on the ipsilateral side
  • Ipsilateral temporal focal hypometabolism on PET
  • Must be agreed by a consensus of ipsilateral mesial temporal origin by a multidisciplinary discussion

Age in the registry: 14 years to 65 years · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

This page is information, not medical advice. Discuss any trial with your doctor.